Neuberger Berman Group
GMAB icon

Neuberger Berman Group’s Genmab GMAB Stock Holding History

Neuberger Berman Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
50,557
-3,405
-6% -$90.5K ﹤0.01% 1411
2026
Q1 		$1.45M Sell
53,962
-2,959
-5% -$88.7K ﹤0.01% 1290
2025
Q4 		$1.75M Buy
56,921
+10,632
+23% +$331K ﹤0.01% 1224
2025
Q3 		$1.42M Sell
46,289
-804
-2% -$19.6K ﹤0.01% 1254
2025
Q2 		$973K Buy
47,093
+2,803
+6% +$57.5K ﹤0.01% 1364
2025
Q1 		$867K Buy
44,290
+10,616
+32% +$223K ﹤0.01% 1365
2024
Q4 		$703K Sell
33,674
-10,349
-24% -$227K ﹤0.01% 1420
2024
Q3 		$1.07M Sell
44,023
-4,097
-9% -$110K ﹤0.01% 1281
2024
Q2 		$1.21M Sell
48,120
-2,098
-4% -$59.5K ﹤0.01% 1218
2024
Q1 		$1.5M Sell
50,218
-27,972
-36% -$822K ﹤0.01% 1186
2023
Q4 		$2.49M Buy
78,190
+34,028
+77% +$1.07M ﹤0.01% 1221
2023
Q3 		$1.56M Buy
+44,162
New +$1.68M ﹤0.01% 1139

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neuberger Berman Group's GMAB Position: Q2 2026 in Review

Neuberger Berman Group reduced its Genmab (GMAB) stake by 6.3% in Q2 2026, selling an estimated $90.5K and leaving 50,557 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Neuberger Berman Group first reported a position in GMAB in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.49M in Q4 2023. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Neuberger Berman Group held 50,557 shares of Genmab worth $1.39M as of Q2 2026.
  • Neuberger Berman Group sold 3,405 Genmab shares in Q2 2026, an estimated $90.5K.
  • Genmab made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1411 holding.
  • Neuberger Berman Group first reported a position in Genmab in Q3 2023 and has held it in 12 quarters since.
  • Neuberger Berman Group's Genmab position peaked at $2.49M in Q4 2023.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.